Form 4: Hongbo Lu, Director at Terns Pharmaceuticals, Reports Significant Stock Purchases

Director Hongbo Lu reports the acquisition of Terns Pharmaceuticals (TERN) common stock through indirect ownership via NEXTBio Master Fund LP and NEXTBio Opportunity Adapt LLC.

Summary

• On September 12, 2024, Hongbo Lu, a director of Terns Pharmaceuticals, reported the acquisition of common stock.
• The purchases were made indirectly through NEXTBio Master Fund LP and NEXTBio Opportunity Adapt LLC.
• 190,476 shares were acquired at a price of $10.5 per share through NEXTBio Master Fund LP.
• 285,714 shares were acquired at a price of $10.5 per share through NEXTBio Opportunity Adapt LLC.
• Following these transactions, the total number of shares beneficially owned indirectly by Mr. Lu is 476,190 through NEXTBio Opportunity Adapt LLC and 190,476 through NEXTBio Master Fund LP.
• Mr. Lu disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: Insider buying is generally viewed as a positive sign, but the disclaimer of beneficial ownership tempers the enthusiasm. The sentiment is neutral to slightly positive.

Positives

• The director's purchase could be interpreted as a positive signal about the company's prospects.

Management Comments

• The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Key Dates